Everest Medicines Reports Results from the P-Ib/IIa Study of EVER001 to Treat Primary Membranous Nephropathy
Shots:
- The P-Ib/IIa study assessed EVER001 (XNW1011) to treat patients (n=31) with primary membranous nephropathy (pMN) in China for 36wks.
- Study (as of Sep 2024) showed overall clinical remission in 81.8% & ICR in 91% by wk.36 across low-dose level, while 86% achieved overall clinical remission & all achieved ICR by wk.24 in high-dosing level; proteinuria reductions were 78.3% (low-dose) & 73.8% (high-dose); anti-PLA2R Ab levels dropped over >90% by wk.24 (low-dose) & wk.12 (high-dose)
- EVER001, covalent reversible BTK inhibitor, is being developed for renal diseases. Everest holds global development, production & commercialization rights under a licensing agreement with Sinovent Pharmaceuticals & SinoMab BioScience
Ref: Everest Medicines | Image: Everest Medicines
Related News:- The NMPA Accepts Everest Medicine's IND Application for Zetomipzomib to Treat Immune Mediated Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
